ADMA Biologics Faces Securities Fraud Class Action Over Revenue Claims

The complaint against ADMA Biologics centers on accusations that the company artificially inflated its financial standing through undisclosed related-party transactions and a practice known as channel stuffing. These actions allegedly created a deceptive appearance of revenue growth, leading to material losses for shareholders once the underlying facts surfaced. The lawsuit asserts that the firm violated the Securities Exchange Act of 1934 by failing to maintain necessary internal controls and issuing false public statements throughout the specified class period.

Shareholders who incurred losses during this timeframe are eligible to seek compensation without upfront out-of-pocket costs. While the class has not yet been formally certified, affected investors may contact attorneys Adam Rosen and David Schwartz at Schall Brown & Schwartz to discuss their legal standing or the potential to serve as a lead plaintiff. Those who choose not to participate remain absent class members, meaning they are not currently represented by specific counsel in this ongoing litigation.